Turning Point Therapeutics

A stock market rebound created a strong finish for biopharma flotations in 2019, with four $100m-plus floats, led by Phathom Pharmaceuticals.

Impressive results in lung cancer with Eli Lilly’s Ret inhibitor set the stage for approval next year, but Blueprint is not far behind.

September 05, 2019

Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.

June 24, 2019

Turning Point is heading into a highly competitive lung cancer niche with its lead project, which still has much to prove.

Latest Reports